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A new technique has been developed for the purification of bovine placental 
lactogen (bPL) from an ammonium sulfate preparation, using an immunomagnetic 
separation process. This alternative procedure is used in cell and molecular biology to 
separate various types of proteins, cells and nucleic acids due to its advantages over the 
traditional methods. The first step of the bPL purification system was to isolate antibody 
(Ab) against bPL, called sheep anti-rabbit antibody. A two milliliter column of 
Immobilized Protein G, elution buffer (pH 2.8) and binding buffer (pH 5.0) were used 
during Ab purification process. The Ab activity was monitored by using a 
radioimmunoassay (RIA) prior to coupling to a biomag, which consists of a suspension of 
magnetic particles coated with iron oxide to provide primarily amine groups. These 
groups allow for covalent attaching to proteins or ligands with maintaining the biological 
activity. A suspension of magnetic iron particles conjugated with sheep anti-rab bit IgG 
was used in the experiment. The coupling efficiency was 80% determined by measuring 
protein concentration at 280nm. The next step was purification of endogenous bPL from 
bovine placental homogenate, which had been prepared by an ammonium sulfate (A.S.) 
precipitation. One gram of dried A.S. dissolved in 40 ml Tris HCI buffer (1OmM pH 7.5) 
was centrifiiged at 10,000 x g for 30 min. The supernatant was collected and mixed with 
5 ml biomag. The particles were recovered with a magnet and the supernatant was 
discarded. This was followed by washing two times with Tris buffer (IOrnM pH 7.5). 
Finally, bPL was eluted from the biomag by adding 10 ml glycine (0.1M pH 3.2). 
Sucrose was then added to the glycine mixture to prevent protein aggregation and stored 
in the refrigerator for analysis. At each step of the purification process, the protein 
content of the sample was estimated by measuring the absorbance of light at 280 
nanometers with a spectrophotometer. The Bradford assay was also utilized for further 
examining of protein level in the sample. The presence of bPL in the sample was 
determined by RIA. The purified bPL fraction was concentrated by lyophilization and 
run on the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to 
determine how pure the bPL is. The purity level of the bPL was 25%, which is higher 
than results obtained in some previous studies using a similar starting material 
preparation. This result, however, is still not much greater than obtained with previous 
conventional bPL purification approaches, and other studies using the immunomagnetic 
separation techniques to isolate the target biomolecules. Thus hrther purification steps 
are required. The purification system described in this study, at present, cannot offer an 
efficient protocol for the isolation of bPL. The developed method, nevertheless, is simple 
and rapid as only a one-purification step is involved. This approach has also reached a 
moderate sensitivity, which may perhaps be refined to enhance the optimization. 
Additional investigations, regarding the conditions of elution buffers and the size of 
magnetic particles, may need to be taken into consideration to obtain a better result. 
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Placentas of primates, rodents and ruminants secrete one or more polypeptide 
hormones, including placental lactogen (PL), prolactin-related proteins (PRPs) and 
placental growth hormone V (GH-V). Among these hormones, PL has been investigated 
most extensively. The term placental lactogenic hormone was originally used, as this 
hormone exhibits prolactin-like (lactogenic) responses in several radioreceptor and 
bioassays (Anthony et al., 1995a). This placental hormone also displays a number of 
somatogenic activities, thus it is also called chorionic somatotropin (Byatt et al., 1992a). 
In the bovine placenta, researchers have discovered six PRPs, which are structurally 
similar to each other but distinct from the structure of bovine (b) PL (Schuller et al., 
1991). There is no indication that these placental proteins are present in horses, pigs and 
rabbits (Anthony et al., 1995a). The placenta of these species probably lacks trophoblast 
binucleate cells (BCs), which are responsible for synthesizing PL. 
Placental lactogen, growth hormone (GH) and prolactin (PRL) belong to a family 
of polypeptide hormones, which are structurally related and share several biological 
features. The primary structure of ruminant PLs has been characterized in cattle (Schuller 
et al., 1988), sheep (Chan et al., 1976; Hurley et al., 1977; Warren et al., 1990a) and goats 
(Sakal et al., 1998). The amino acid (AA) sequence of ovine (0) PL was 67% identical 
with bPL (Warren et al., 1990a), while the similarity between oPL and caprine (c) PL was 
higher (85%) (Sakal et al., 1998). These data indicated ruminant PLs are structurally 
more similar to PRL than to GH in the nucleotide and AA sequence, whereas human (h) 
PL has a structure more related to hGH (Bewley et al., 1972) than to PRL (Shome and 
Parlow, 1977). These have contributed to the suggestion that the gene for rodent and 
ruminant PLs evolved from the prolactin gene family (Anthony et al., 1995b; Hurley et 
al., 1977). 
Structure 
The presence of PL throughout pregnancy has been described in the human, 
monkey (Kaplan and Grumbach, 1964), goat (Buttle et al., 1972), sheep (Martal and 
Djiane, 1975) and cow (Bunle and Forsyth, 1976). The purification of bPL was initially 
reported with the molecular weight (MW) of 22,150 and isoelectric point (PI) of 5.9 
(Bolander and Fellows, 1976). However, other laboratories have not been able to repeat 
these findings. To clarify the situation, bPL purification and characterization were 
reported by a number of studies, reporting the MW of bPL ranges from 30,000 to 32,000 
(Murthy et al., 1982; Eakle et al., 1982; Arima and Bremel, 1983; Wallace, 1986). The 
MW of PLs in sheep (Martal and Djiane, 1975; Warren et al., 1990b) and goat (Currie et 
al., 1990) were found to be about 22,000, which was similar to the MW of hPL and 
monkey PL (Shome and Friesen, 1971). Clearly, the MW of bPL is different from PLs in 
all other known species, except for mouse PL, which exists in two forms of glycoprotein 
with different MW, ranging between 29,000-32,000 and 36,500-42,000 (Colosi et al., 
1987). 
Bovine PL has been shown to exist in at least three forms, which differ in 
isoelectric points and acidic AA compositions (Arima and Bremel, 1983). A structural 
comparison between bPL, oPL and cPL indicated that bPL contains unusual carbohydrate 
residues in its structure, including N-linked and 0-linked oligosaccharides (Byatt et al., 
1990), whereas oPL and cPL are nonglycosylated polypeptides (Warren et al., 1990b; 
Currie et al., 1990; Anthony et al., 1995a). These observations suggested that 
glycosylation of bPL may account for the high MW and multiple isoelectric variants. 
Previously, it was suspected that glycosylation related to the multiple isoforms of bPL 
(Shirnomura and Bremel, 1988). Subsequent studies observed that the number of 
isoforms does not change after deglycosylation (Byatt et al., 1990), thus variant genes are 
not responsible for these iso forms. Sequence analysis indicated that two splicing variants 
for bPL exist (Kessler and Schuller, 1991). This gave rise to the possibility that the 
existence of multiple isoforms of bPL may be involved in additional splicing patterns, 
thus translating different final products. 
In cattle, recombinant (r) bPL has been produced in Escherichia coli, but unlike 
the native bPL, this is an unglycosylated protein hormone (Krivi et al., 1989). The effect 
of enzymatic deglycosylation of bPL on receptor binding and biological activity has been 
investigated using a somatotropin radioreceptor assay and the Nb2 lymphoma assay for 
lactogenic activity (Byatt et al., 1990). This data indicated removal of N-linked 
oligosaccharides from native bPL increased the binding of bPL to GH receptor (about 1.2 
to 2.3 fold), whereas removal of 0-linked sugar chains had no effects on the prolactin- 
like activity of bPL. Glycosylated and unglycosylated forms of bPL had slightly different 
affinities for the bGH receptor (R) and had no effect on lactogenic binding sites, 
suggesting that glycosylation may not be required for biological function of bPL. Thus 
the biological effects mediated by recombinant bPL may not be different from those 
mediated by native bPL hormone. Recombinant PLs in sheep (Colosi et al., 1989; Sakal 
et al., 1997) and goats (Sakal et al., 1998) can also be prepared in large amounts, thus 
facilitating both in vitro and in vivo studies. 
Biosynthesis of placental lactogen (PL) 
In ruminants, the mode of delivery of PL into the maternal circulation is a process 
of migration and bsion of fetal binucleate cells (BCs) into the maternal endometrial 
epithelium. These cells are produced and developed in the fetal trophectoderm. When 
they mature (filly granulated), they migrate out of the fetal tissue, across the fetal- 
maternal placenta interface, and hse  with maternal uterine epithelial cells. This leads to 
the formation of either transient trinucleate cells (TCs) in cattle, or persistent syncytium 
in sheep and goats (Wooding et al., 1981; Wooding, 1984; Wooding et al., 1986; 
Wooding et al., 1992; Duello et al., 1986; Morgan et al., 1990). Since the chorionic BCs 
in sheep produced an oPL messenger ribonucleic acid (mRNA) (Kappes et al., 1992), 
their migration appears to be essential to the transfer of the non-difisible PL molecule 
across the placenta into maternal compartment. These findings also emphasize an 
important role of fetal BCs in the secretion and storage of PL. 
There is little information concerning the mechanism by which PL is delivered 
into the fetal circulation. It has been established that the release of oPL into fetal 
circulation was probably controlled differently and was not derived from the maternal 
system (Schoknecht et al., 1991). Pregnant ewes and fetuses treated with ornithine, a 
potent stimulus of PL secretion, increased oPL concentrations in maternal plasma but not 
in the fetus (Grandis and Handwerger, 1983). The different effects of ornithine on both 
systems indicated discrete mechanisms for oPL secretion, into the two circulatory 
systems. The findings that radiolabbeled oPL lacked the ability to cross the placental 
barrier when inhsed into either maternal or fetal circulation (Reddy and Watkins, 1983), 
may support this interpretation. It is proposed that PL secretion into fetal circulation may 
result from either a population of BCs, which migrate across the placental barrier and 
release PL into both circulations, or from a population of fetal BCs that do not migrate 
across the pIacenta (Grandis and Handwerger, 1983; Kappes et al., 1992). Another 
possibility is that fetal PL is synthesized from some fetal organs and then directly 
secreted into fetal blood (Handwerger and Freemark, 2000). 
Pattern of PL secretion 
The pattern of PL secretion during pregnancy has been shown to be similar 
among species, including humans (Kaplan and Grumbach, 1965), sheep (Handwerger et 
al., 1977), goats (Currie et al., 1990), rats (Robertson and Friesen, 1981), mice (Soares et 
al., 1982) and cattle (Wallace, 1993). These PL hormones increase with advancing 
gestational age, peak during the last trimester, then decrease at or near parturition. 
However, the concentration of PL in maternal and fetal circulations is highly species 
dependent. 
Maternal PL concentration: The expression of rnRNA for bPL was observed in the 
bovine conceptus beginning at day 17 of pregnancy (Kessler et al., 1991), and was 
correlated with the appearance of fetal BCs (Flint et al., 1979). Maternal bPL secretion 
has been detected in the dairy cows as early as day 63 of gestation, with highest 
concentrations occurring at day 215, and remaining high until just before delivery 
(Wallace, 1993). The presence of oPL was detectable in the trophoblastic tissue at days 
16-17 of pregnancy (Marta1 and Djiane, 1977). The concentration of oPL in maternal 
serum was first detected at day 41-50 (Handwerger et al., 1977), peaked at days 120-140 
of gestation (Handwerger et al., 1977; Gluckman et al., 1979, Taylor et al., 1980), 
gradually declined thereafter, and was significantly lower on the day of delivery (Taylor 
et al., 1980). In goats, the first appearance of cPL was detected in maternal serum on day 
44, peak concentrations occurred during the last third of pregnancy, and declined before 
parturition (Currie et al., 1990). 
It has been suggested that, the pattern of bPL secretion in cattle is distinct from 
that of other species, even from closely related animals such as sheep and goats. The 
highest concentration of bPL (<3 ng/ml, Wallace, 1993) was much lower, as compared to 
peak maternal PL levels in other species, including in sheep (> 900ng/ml, Kappes et al., 
1992), goats (1004ng/ml, Currie et al., 1990), mice (>250ng/ml, Soares et al., 1982), rats 
(400 nglml, Robertson and Friesen, 1981) and humans (> 4000 nglml, Sciarra et al., 
1968). The reasons why levels of PL in the cow are much lower than those of other 
species are not filly characterized. Differences in migration patterns of the BCs among 
species, may explain the observed variations. It can be added that the rapid clearance rate 
of bPL from the blood, may also contribute for the low concentration of a hormone in the 
maternal circulation. The disappearance of recombinant bPL from maternal plasma was 
reported to be 7.25 min (Byatt et al., 1992c), which is thus removed from the circulation 
faster than most hormones reported, such as oPL (12.7 min, Reddy and Watkins, 1983), 
hPL (21-23 min, Beck et al., 1965), bGH (28min, Hart et al., 1980), bPRL (20-30 min, 
Akers et al., 1980). However, the serum-half life of native bPL may be longer because it 
is glycosylated (8.93 rnin, Torto, 1994). 
Fetal PL concentration: The average concentration of bPL in fetal plasma was about 8 
to 18 fold greater than that in maternal plasma (Holland et al., 1997). The highest 
concentration of bPL in fetal blood ranged between 11.6-18.4 ng/ml, and gradually 
declined with advancing fetal age (Byatt et al., 1987). Although the concentration of bPL 
in fetal serum decreased throughout gestation, the level of bPL in the fetus is always 
higher than in maternal blood. Nevertheless, the much higher volume of maternal blood 
compared to that of the fetus, indicates large amounts of bPL are secreted into the 
maternal system. 
Unlike in cattle, oPL in maternal blood exceeds the fetal level. Maternal serum 
concentration of oPL was 417.7 ng 1 ml on day 105, whereas fetal concentration was 29 
ng/ml on day 90 of pregnancy (Kappes et al., 1992). Fetal oPL levels increased from days 
60-120, peaked by mid-gestation, then stabilized or declined until term (Kappes et al., 
1992; Gluckman et al., 1979; Taylor et al., 1980). Similar to sheep, the average 
concentrations of hPL in the fetus were approximately 350-fold less than those in 
maternal blood (Houghton et al., 1984). 
Factors involving PL secretion: Possible factors involved in PL secretion in maternal 
and fetal serum include: stages of gestation, placental mass, fetal weight, litter size, the 
breed of fetuses and nutritional status. Concentrations of bPL in maternal serum 
increased as gestation progressed (Wallace, 1993). Secretion of bPL was affected by 
nutrient intake and body condition scores (BSC) with thin cows having greater plasma 
bPL concentrations than moderatetely conditioned cows, between days 200 and 256 of 
gestation (Rasby et al., 1990). Pregnant Holstein heifers fed a low crude protein (10.3 %) 
all forage diet had elevated bPL concentrations in maternal blood (Torto, 1994). 
Differences in maternal bPL concentrations were demonstrated in dams bearing different 
breeds of fetuses (Guiltbaut et al., 1990). Concentrations of bPL in maternal blood were 
not affected by the number of fetuses being carried (Pate1 et al., 1996). Unlike cattle, 
serum PL concentrations in goats and sheep are highly correlated with litter sizes. 
Secretions of PL increased as the number of fetuses and placental weight increased in 
sheep (Butler et al., 1981) and goats (Hayden et al., 1980). Prolonged restriction of feed 
intake (72h) in pregnant ewes increased oPL concentrations both in maternal and fetal 
circulations (Brinsmead et al., 198 1). Restriction of placental growth declined the 
production of oPL in the ewes and slightly declined fetal oPL levels (Falcorner et al., 
1985). Maternal plasma hPL increased significantly in pregnant women during fasting 
(Kim et al., 1971). Similar to sheep and goats, a significant correlation has been shown 
between fetal numbers, gestational stages and maternal hPL levels, greater PL 
concentrations were observed in multiple as opposed to singleton gestations (Spellacy et 
al., 1978). Serum hPL levels have also been correlated with placental weight, which is 
influenced both by the stage of gestation and number of fetuses, and the weight of the 
newborn at delivery (Sciarra et al., 1968; Houghton et al., 1984). 
Mechanism of action of ruminant placental lactogens 
It is well documented that PL is one of a group of polypeptide hormones, which 
are structurally related to pituitary GH and PRL. Similar to many protein hormones, PL 
initiates its biological action by binding to its specific receptor on the membrane of target 
cells. Since ruminant PLs have the ability to bind, and activate both PRL and GH 
receptors from other species, they probably have multiple biological effects similar to GH 
and PRL. However, the mechanism of action by which PL binds to its receptors, and the 
biological activities transduced as a result of this interaction, is not filly understood. It 
has been postulated that ruminant PLs may initiate their biological signals through 
several possible ways: (1) activating a unique PL-R; (2) activating a variant form of GH- 
R; (3) dimerizing GH-R fiom heterologous animals, but not from homologous (ruminant) 
species; (4) heterodimerizing GH and PRL receptors in ruminants; (5) transducing the 
signals through PRL receptors in both heterologous and homologous species. 
Activating a unique PLR: Ruminant PLs may initiate biological activity through a 
specific receptor, which is structurally distinct from the GH-R. Specific binding sites for 
bPL, but not for bGH, were identified in the uterine endometrium of pregnant cows, 
suggesting bPL may act through a distinct bPL-R in the endometrium, to maintain 
pregnancy (Galosy et al., 1991). Specific receptors for bPL were also found in 
membranes isolated from bovine luteal tissue that displayed high affinity for bPL, but 
very low affinity for either bGH or bPRL (Lucy et al., 1994). In contrast, both bGH and 
bPL bound to bGH-R in the hepatic bovine membrane with high affinity (Byatt et al., 
1995). These findings raise a possibility that in liver tissue, bPL may exert its actions 
through either bGH or bPRL receptors, whereas in the uterus and corpus luteum (CL) 
membranes, bPL may act through a unique PL -R. 
An in vivo study with mature female rats has shown that bPL exhibited an acute effect on 
weight gain at a low dose, and increased feed intake to a greater extent, as compared to 
bGH (Byatt et al., 1991). Studies in dairy cows reported bPL displays distinct effects on 
intermediary metabolism (Byatt et al., 1992c) and feed intake (Byatt et al., 1992b), as 
compared to bGH. These observations indicated that bPL might work through a 
mechanism that is different fiom that of bGH. 
In sheep, the presence of a specific oPL-R in the liver of fetuses and pregnant 
ewes was also reported (Freemark and Handwerger, 1986; Freemark et al., 1987). In 
ovine fetal tissues, oPL-stimulated glycogen synthesis occurred to a greater extent (1 8- 
167%), as compared to oGH (12%) and oPRL (4%) (Freemark and Handwerger, 1986). 
Specific binding for oPL was hrther shown in CL in sheep (Chan et al., 1978). A distinct 
effect of oPL on food intake, as compared to bGH, was also observed in young lambs 
(Min et al., 1996). Subsequent reports demonstrated oPL has an indirect effect on the 
fetal somatotropic axis, by increasing the expression of insulin-like growth factor binding 
protein 3 (IGFBP-3) in the fetal liver, whereas oGH treatment does not have comparable 
effects (Currie et al., 1996). These data proposed that the metabolic effects of oPL might 
be mediated through binding to a specific PL-R. 
Activating a variant form of GH-R: Another possibility is that ruminant PLs may act 
by homodimerizing of a modified GH-R, which is mutated at its extracellular domain 
(ECD) in a way that allows dimerization of GH-R. Two types of rnRNA (4.7 and 4.4 kb) 
for GH-R were found in bovine CL and ovary, whereas only a single type (4.4 kb) was 
detected from the liver (Lucy et al., 1993). Further investigations suggested that bPL may 
bind to the CL through a modified (4.7 kb) form of the bGH-R (Lucy et al., 1994). In 
addition, in the bovine liver, the ECD of bGH-R binds to bGH and bPL with high affinity, 
but with different stoichiometry (Staten et al., 1993). While bGH binds to the bGH-R in 
a 1 :2 ratio (1 bGH: 2bGH-R), bPL does not cause homodimerization of the bGH-R. These 
data suggested that the ECD of bGH-R could be modified, and these conformational 
changes, increase binding specificity for bPL, but significantly reduce affinity for bGH 
(Byatt et al., 1995). 
Overall, available evidence indicates the presence of specific ruminant PLs, and 
some efforts have been made to purify and characterize the distinct PL-R (Freemark and 
Comer, 1989). However, the unique PL-R has not yet been isolated up to date. Thus, the 
question of whether the unique PL-R exists or whether ruminant PLs work through a 
modified GH-R remains unsolved. 
Homodimerizing of GH-R from homologous species: Research has shown that in 
heterologous species (rats, rabbits, humans), ruminant PLs can mimic GH actions by 
dimerizing GH-R. However, in homologous (ruminant) systems, PLs can bind to, but not 
homodimerize ruminant GH-Rs. Utilizing in vitro heterologous systems, using rat 3T3- 
L1 adipocytes to examine the somatogenic activity, Byatt and coworkers (1991) found 
both bPL and bGH are similar in their ability to inhibit the insulin-stimulated glucose 
uptake. A hrther study reported that in 3T3-F442A rat preadipocyte bioassays that the 
somatogenic activity of bPL is slightly less potent (six-fold lower) than hGH (Vashdi et 
al., 1992). However, in primary cultures of rat hepatocytes, bPL was approximately 100- 
fold more potent than bGH in inducing an insulin-like growth factor I (IGF-I) mRNA 
expression (Warren et al., 1993). IGF-I and IGF-I1 are characterized as serum 
polypeptides, which play an important role in regulating growth. Similar results have 
been observed in sheep and goats. The mitogenic activity of oPL or cPL was as potent as 
hGH in two heterologous bioassays using FDC-1 cells transfected with rabbit or human 
GH receptors (Sakal et al., 1997; Sakal et al., 1998). Interaction studies have 
demonstrated that, bPL is capable of forming 1:2 complexes with hGH-R (Vashdi et al., 
1995; Helman et al., 1998) and rabbit GH-R (Helman et a]., 1997). Gel-filtration 
experiments also observed oPL and cPL form 1 :2 complexes with rabbit GH-R or hGH-R 
(Sakal et al., 1997; Sakal et al., 1998, Helman et al., 1998). Results of these data clearly 
documented that ruminant PLs have capacity to homodimerize GH-Rs in heterologous 
species. 
Results from studies with rats have proven that bPL displays more potent 
somatogenic activity (stimulating weight gain) as compared to bGH (Byatt et al., 1991). 
Similar to cattle, oPL also showed a greater growth-promoting effect, as compared to 
bGH, in GH-deficient dwadrats (Singh et al., 1992). In contrast, studies with cattle have 
shown bPL could not mimic all of the metabolic effects of bGH, indicating that in 
homologous species bPL only acts as a weak GH agonist (Byatt et al., 1992b). The fact 
that in the bovine liver bPL interacted with bGH-R with about three-fold less potency 
than bGH (Byatt et al., 1991), may be one of the relevant reasons to explain why bPL 
only displays partial somatogenic responses in dairy cows as compared to bGH. 
There has been controversy in reporting that bPL has somatogenic activity in vivo, 
but does not induce homodimerazation of the bGH-R. A number of studies have been 
performed to reexamine the activity of ruminant PLs through homologous and 
heterelogous GH-Rs. A homologous bioassay was carried out using two cell lines Ba/F3- 
C1 and BHK-24, which are transfected with bGH-R, to evaluate proliferative and cellular 
signaling differences between bPL and bGH (Warren et al., 1999). The results showed 
that bGH stimulates mitogenic activity and phosphorylation of JAK2, a tyrosine kinase 
responsible for the signal transduction downstream of the receptor, while bPL was not 
involved in either process, despite both hormones binding to bGH-R with a similar 
affinity. These findings were consistent with previous experiments using a murine 
lymphoid cell line, Bafl3 (Warren et al., 1997). The lack of biological responses resulting 
from bPL binding to the bGH-R indicated that this might be due to an inability of bPL to 
induce dimerization of bGH-Rs. These observations suggested that homodimerization of 
bGH-R may be essential for these biological activities (Warren et al., 1999). 
Cunningham and coworkers (1991) used the human GH model system to 
demonstrate that the sequential: dimerization is important for activation of cytokine 
receptors. They observed that the hGH molecule has two separate sites for receptor 
binding, termed sited 1 and site 2. In order to produce an active homodimer (1 hGH : 2 
hGH-R), at first GH-R binds to site 1 on GH, and subsequently at site 2 to on the same 
molecule of GH. This active molecule was required for intracellular signaling by the GH- 
R and for phosphorylation of cellular proteins through activation of tyrosine kinase (Silva 
et al., 1993). However, excess hGH antagonized signaling by preventing 
homodimerization. This leads to a formation of an inactive 1: 1 complex, which acts as a 
somatotropin antagonist. Similarly, Fuh and his coworkers (1 992) also observed mutant 
GH, which lacks binding site 2 and possesses only site 1, can antagonize signaling by 
preventing dimerization. They also found the proliferation of FDC-PI cells is lost at very 
high hGH concentrations. Later studies by Herman and coworkers (1999) supported 
previous findings. They demonstrated that oPL is inactive or antagonistic to the 
mitogenic activity of oGH in homologous bioassays using "293" cells transfected with 
full size oGH-R. The activity of cPL and bPL was similar to that of oPL. In contrast, all 
three PLs acted as agonists in heterologous bioassays in cells transfected with either 
rabbit GH-R or human GH-R. Although these hormones differ in their activities, oGH 
and PLs bind to oGH-R with similar affinity, indicating that the binding occurs through 
site 1 of the hormones. This interpretation is consistent with most studies, implying that 
ruminant PLs form only 1: 1 complexes with oGH-R (Herman et a]., 1999), or bGH-R 
(Staten et al., 1993). Taken together, these data support a new theory, that in homologous 
systems, ruminant PLs antagonize the mitogenic activity of GH because they do not 
homodimerize GH-Rs, whereas in heterologous species they do, and thus act as an 
agonist. 
Heterodimerizing of GH and PRL receptors from ruminant animals: Another 
assumption has implicated that ruminant PLs may transduce biological signals by 
heterodimerization of homologous GH and PRL receptors. An experiment was conducted 
to investigate whether ruminant PLs can initiate a biological signal by heterodimerizing 
GH and PRL receptors (Herman et al., 2000). A significant result of this experiment was 
that a triple complex with a high molecular mass consisting of three components of oPL, 
oGH-R and bPRL-R was detected (bPRL-R was used instead of oPRL-R since these 
proteins have a high percentage of similarity (96%) and exhibit similar activity in cells 
transfected with PRL-R). These results were obtained by using a novel method, based on 
surface plasmone resonance (SPR), to measure the real-time kinetic interaction between 
molecules and the stoichiometry of a complex (Johnsson et al., 1991). It has been 
described that the heterotrimeric complex is formed by consecutive binding of oGH-R 
through site 1 of immobilized oPL and bPRL-R through site 2 of the same oPL molecule. 
Their results also showed that oPL or bPL significantly enhances bioactivity in 
cotransfected cells with oGH-R and oPRL-R, while little or no biological signal is 
observed in cells transfected with oGH-R or oPRL-R alone. Subsequent SPR studies also 
indicated the kinetics of interactions are different (Gertler et al., 2002). Their results 
indicated that whereas the 1 : 1 (oPL:oGH-R) complex has a half-life of about 50 min, the 
interaction between the 1 : 1 complex and bPRL-R is very unstable, with a half-life of less 
than 0.2 min. This transient complex has been detected in SPR studies, but not by gel- 
filtration experiments, due to its rapid dissociation to the 1 : 1 form (Gertler et al., 1996). 
Recent work by Biener et al., (2003) confirmed a unique property of oPL in its ability to 
heterodimerize homologous GH-R and PRL-R. Together, these data provide evidence 
that heterodimerization between two distinct cytokine receptors does occur and leads to 
initiation of signal transduction. 
Additional in vivo evidence, supporting the new hypothesis reported that co- 
administration of bGH with oPL to postnatal lambs for 5 days elevated IGF-I levels more 
than that stimulated by bGH or oPL alone (Ogawa et al., 1995). Short-term (9 d) 
administration of bPL to dairy cows increased milk yield, although bPL was less potent 
than bGH (Byatt et al., 1992b). Lactating ewes treated with oGH or oPL for 14 days 
increased milk yield, but oGH was significantly more potent than oPL (Leibovich et al., 
2001a). Since ruminant PLs only mimic partial GH-like galactopoiesis, it is thought that 
these effects are likely achieved by the heterodimerization of PL with homologous GH 
and PRL receptors. 
Activating PRL-Rs from both heterologous and homologous species: It has been 
suggested that ruminant PLs may act by activating PRL-Rs in both homologous and 
heterologous systems. Accumulating evidence indicates that ruminant PLs have an ability 
to act in cells possessing both homologous and heterologous PRL receptors. In an vitro 
heterologous bioassay, bPL had the capacity of acting through PRL-Rs to stimulate 
proliferation of rat Nb2 lymphoma cells (Byatt et al., 1990). Bovine PL also stimulated a- 
casein (milk protein) synthesis in mammary gland explants from pseudo-pregnant rabbits 
(Bignon et al., 1994). Lactogenic activity of oPL and hGH were equipotent in Nb2 cell 
proliferation bioassay (Sakal et al., 1997). The synthesis of p-casein by oPL and cPL was 
significantly greater than that of oPRL in rabbit mammary gland explants (Sakal et al., 
1997; Sakal et al., 1998). By contrast, in homologous bioassays, in ovine mammary gland 
explants the p-casein production induced by oPL was slightly less potent, as compared 
with oPRL (Sakal et al., 1997). A recent homologous bioassay has also confirmed that, 
the lactogenic activity of oPL, is less potent than that of oPRL in HEK 293 cells 
transfected with oPFU-R (Leibovich et al., 2001b). 
To gain hrther knowledge, some researchers have investigated the interaction of 
various lactogenic hormones with PRL-Rs prepared from several species, using both gel 
filtration and SPR experiments. Their results showed that bPL forms 1 :2 complexes with 
PRL-R in both heterologous and homologous species, such as rabbits (Bignon et al., 
1994), rats (Tchelet et al., 1995; Helman et al., 1998) and the cow (Gertler et al., 1996). 
Similar results were observed with oPL (Sakal et al., 1997; Helman et al., 2001) and cPL 
(Sakal et a]., 1998). The fact that ruminant PLs are able to interact with various PRL-Rs 
in both homologous and heterologous systems to form a homodimer, together with the 
previous experiments, which noted that ruminant PLs are lactogenic in vivo, suggests that 
ruminant PLs can act through homologous PRL-Rs, although they are not a potent 
lactogen in homologous species. These results could be due to the lower binding affinity 
of oPL to ewe mammary glands, as compared to rabbit mammary tissues (Servely et al., 
1983), and due to lower affinity of oPRL, bPRL, bPL to bPRL-R, as compared to hGH 
(Tchelet et al., 1995; Sakal et a]., 1997). Some recent studies have demonstrated the 
mechanism of ruminant PL actions that gave rise to another possible explanation that in 
homologous species ruminant PLs may act by heterodimerizing GH and PRL receptors, 
thus exhibiting bioactivities that are distinct from that of PRL or GH. Whereas in 
heterologous species, the PL signal may be transduced through homodimerization of GH- 
R, thereby displaying similar GH-like galactopoiesis. 
To better understand the differences between the activities transduced through 
heterologous and homologous PRL-Rs, a novel hypothesis has been developed, namely 
"a mimimal time of homodimer persistence" (Helman et al., 2001). It is assumed that, in 
order to initiate the hormonal signal transduction, the associated kinase JAK2 has to be 
transphosphorylated and this requires a minimal time of homodimer existence. In the case 
of homologous interactions, even though the transient dimerization of PRL-R with 
ruminant PLs lasted only a few seconds, this minimal time was still sufficient to elicit a 
f i l l  biological response (Gertler et al., 1996). Thus, ruminant PLs are able to act via the 
lactogenic receptor, in both homologous and heterologous systems, despite the fact that 
the binding properties and stoichiometries of interaction in homologous species are 
different from those of heterologous systems. 
Biological functions of ruminant placental lactogens 
The biological functions of PLs are generally not fully understood. They probably 
have multiple biological effects related to luteotrophic activity, mammogenesis, 
lactogenesis, somatogenesis and fetal development. 
Luteotrophic action: Factors that stimulate corpus luteum (CL) function are referred to 
as luteotrophic. Progesterone secreted by the CL is essential for the maintenance of early 
pregnancy in all farm species. In sheep, after day 50 the ovary is no longer required for 
the maintenance of pregnancy, since the placenta secreted large amount of progesterone 
(Bassett et al., 1969). By contrast, in goats, cows and rodents the CL alone is responsible 
for progesterone throughout the whole pregnancy. 
It has been reported that ovarian function can be modified by bGH, and similar 
changes may occur with bPL in the cow. During an estrous cycle, administration of bGH 
increased the number of ovarian follicles in lactating cows (Delasota et al., 1993) and 
heifers (Gong et al., 1991). Injections of recombinant bGH to lactating dairy cows 
increased plasma progesterone concentrations (Schemm et al., 1990; Gallo et al., 199 l), 
and the weight of the CL (Lucy et al., 1992). The presence of bGH-R was detected in 
both bovine CL (Scott et al., 1992) and ovary (Lucy et al., 1993). These findings inferred 
that bGH might have direct effects on the bovine ovary and CL through binding to GH-R 
and these effects may correlate with an increase in circulating IGF-I concentrations (Peel 
et al., 1987). 
Later work found that both recombinant bGH and bPL have stimulatory effects on 
the development of the CL and ovarian follicles in heifers, but their effects appear not to 
be identical (Lucy et al., 1994). While bPL displayed higher potency in stimulating CL 
growth and progesterone secretion, the potency of bGH was greater in stimulating the 
IGF-I concentration and the second largest follicle development. Both hormones caused a 
similar effect in inhibiting preovulatory follicle development. The existence of specific 
binding sites, which displayed high-affinity for bPL, but not bGH (Lucy et al., 1994), 
together with the presence of a modified mfWA for bGH-R found within the CL (Lucy et 
al., 1993), caused speculation that, bPL may act by binding to an altered form of the 
bGH-R to support CL development and inhibit follicular growth during pregnancy. This 
hypothesis, however, is still being debated. 
Reports on the luteotrophic role for oPL have been conflicting. Early work with 
ewes had shown the presence of a specific binding site for oPL in ovine CL membranes 
(Chan et al., 1978). This report was in contrast to other experiments, which showed oPL 
does not have the ability to stimulate progesterone secretion, or to protect the CL against 
the luteolytic action of prostaglandin F (PGF2,) when inhsing oPL for 2h into the ovary 
of the sheep (Schramm et al., 1984). A later experiment indicated immunoneutralization 
of oPL for 12h has no effect on progesterone concentration in late pregnant ewes (Waters 
et al., 1985). A recent experiment confirmed the luteotrophic and luteoprotective actions 
of oPL on the CL obtained fiom pregnant ewes (Gregoraszczuk et al., 2000). Their 
results showed that oPL stimulated luteal cells isolated on days 45 and 70 of gestation to 
produce progesterone, suggesting a direct luteotrophic effect on the CL during the early 
half of pregnancy. This data was consistent with the results of Chan and his co-workers 
(1978), who suggested oPL binds specifically to the ovine CL membrane. Other reports 
also emphasized that oPL is luteotrophic on luteal cells, obtained at days 40-45 of 
gestation whereas both oGH and oPRL do not cause significant effects (Wierzchos et al., 
2000). Additionally, it has been observed that co-administration of oPL and PGF2, 
significantly increased progesterone secretion by luteal cells isolated on days 70 and 95 
of pregnancy whereas a PGF2, treatment alone decreases progesterone secretion, which 
implies the role of oPL against luteolytic action of prostaglandin (Gregoraszczuk et al., 
2000). Further evidence has been given in rodents, indicating the mouse ovary contains 
receptors that specifically bind to mouse PLs (MacLeod et al., 1989) and maintain 
progesterone secretion during the later half of pregnancy (Galosy and Talamantes, 1995; 
Thordason et al., 1997). Thus, available information reported fiom various species 
indicates the important role of PLs on the CL function during pregnancy. However, the 
mechanism of action controlling this process remains unclear. 
A homologous bioassay, using HEK 293 cells transfected with either oPRL-R or 
primarily luteal cells, was conducted to compare the luteotrophic activity of oPL with 
oGH and oPRL (Leibovich et al., 2001b). These results showed that oPL significantly 
increased progesterone secretion in ovine luteal cells collected on days 17 and 45 of 
pregnancy, whereas oPRL and oGH had no such effects. On the other hand, all three 
hormones hrther increased progesterone secretion (about seven to eight fold), in the 
primary culture of luteal cells obtained from mid-pregnant ewes. Since both oPRL and 
oGH were inactive in stimulation of progesterone production during early pregnancy, 
these observations suggested that in early gestation, the luteotrophic effects of oPL are 
probably obtained via heterodimerizing PRL and GH receptors. Later in gestation 
(midpregnancy), however, the luteotrophic effects of oGH and oPRL were achieved 
through activating their unique receptors, whereas oPL acted, either by activation of 
PRL-Rs, or heterodimerizing homologous GH and PRL receptors (Leibovich et al., 
2001 b). 
Mammogenesis: Mammary growth (mammogenesis) is known to occur predominantly 
during late pregnancy, when PL is at a high concentration, indicating this hormone may 
be related to mammogenesis and lactogenesis. It is well known that the lobulo- alveolar 
cells of the mammary gland are stimulated by PRL, thus depression of PRL 
concentrations by bromocryptine treatment inhibited mammary development in non- 
pregnant-ewes (Schams et al., 1984). During pregnancy, however, bromocriptine 
administration did not affect mammary development of sheep, cattle (Schams et al., 1984) 
and goats (Forsyth et al., 1985). These data suggest that ruminant PLs may act on the 
mammary glands and may substitute for prolactin to support mammary growth during 
pregnancy. 
In cattle, bPL increased deoxyribonucleic acid (DNA) synthesis in bovine 
mammary transplants maintained in nude mice, suggesting a mammogenic role for bPL 
(Vega et al., 1989). In addition, rbPL has been shown to stimulate total mammary DNA 
in dairy heifers, but this effect does not occur in groups treated with a high level of 
rbPRL (80 mgld) (Byatt et al., 1994). They also observed that both hormones induce 
mammary differentiation (milk synthesis), although bPRL appears more potent than bPL. 
Further evidence indicated that PRL is required for lactogenesis rather than for mammary 
growth in periparturient cows (Akers et al., 1981; Collier et al., 1993). These results 
suggested that bPL stimulates mammogenesis and that a high level of prolactin is not 
required for mammary growth in cattle. Moreover, a positive relationship between rbPL 
concentration and milk production was found in dairy heifers (Byatt et al., 1997). These 
data support the hypothesis that bPL is one of the factors that is involved in mammary 
development during pregnancy. 
Although bPL has been shown to bind to bPRL-R with high affinity (Scott et al., 
1992), this hormone also binds to bGH-R (Byatt et al., 1990). It is not clear whether the 
mammary response to bPL is mediated directly by the mammary tissue or via an indirect 
mechanism. Collier and coworkers (1993) demonstrated that PLY GH and PRL do not 
appear to affect mitogenic activity of bovine mammary epithelial cells (BMEC) in vitro, 
using mammary tissue obtained from non-lactating heifers at 150 days of pregnancy. 
However, GH and PL increased BMEC DNA synthesis in late pregnant cows or dairy 
heifers when directly infused into the mammary gland. On the other hand, IGF-I 
displayed a positive effect both in vitro and in vivo. These results suggested the effects of 
GH and PL on mammary growth are probably regulated via members of the 
somatomedins, rather than directly via a lactogenic receptor pathway. These explanations 
are supported by the direct in vifro study of IGF-I that demonstrated that IGF-I and-I1 
increased proliferation of BMEC (McGrath et al., 1991). In dairy cows, rbPL also 
increased IGF-I and I1 concentrations, despite being less potent than bGH (Byatt et al., 
1992~) .  Furthermore, rbPL was more active than rbPRL in stimulating mammary 
secretion of IGFBP-2 and -3 (Byatt et al., 1994). Clearly, members of the somatomedins 
are important mediators of mammary epithelial growth in ruminants. 
In sheep, oPL was very efficient in stimulating p-casein synthesis from the 
mammary glands of rabbits but not from ewes (Severly et al., 1983; Sakal et al., 1997). 
Similar results were reported for PL in goats (Sakal et al., 1998). In contrast to cattle, oPL 
was unable to compete for prolactin binding sites in the ovine mammary gland (Emane et 
al., 1986). These observations suggested that oPL might not play an important role in 
mammogenesis and lactogenesis in ewes. Later work has emphasized that recombinant 
oPL and oGH have mammogenic effects in ewes, via stimulating the development of 
lobulo-alveolar systems (Kann et al., 1999). They also found, both hormones increase 
plasma IGF-I concentrations, although oPL is less efficient than oGH. These results 
agreed with other experiments indicating that IGF-I increased DNA synthesis of ovine 
mammary cell in cultures (Winder et al., 1989). Together, these data suggest that oPL and 
oGH are mammogenic in ewes and IGF-I could be one of the mediators of these 
hormones. 
Lactogenesis: Factors that stimulate the mammary gland to synthesize milk proteins are 
defined as being lactogenic (Soares et al., 1991). In vitro studies across species have 
demonstrated that bPL specifically binds to PRL-R in rabbit liver membranes (Eakle et 
al., 1982) and rabbit mammary explants (Byatt and Bremel, 1986), suggesting bPL is 
lactogenic in this species. The potency of bPL was comparable to that of bPRL in the 
rabbit Nb2 cell proliferation bioassay (Murthy et al., 1982). In IM-9 human lymphocytes, 
bPL was as potent as hGH in its ability to bind to hGH-R (Vashdi et al., 1995). By 
contrast, in homologous bioassay, using mammary gland explants from pregnant heifers, 
bPL failed to stimulate the production of lipid, casein and a-lactabumin, which is 
required for lactose synthesis, suggesting bPL is not galactopoietic in the cow (Byatt and 
Bremel, 1986). Galactopoiesis is defined as milk synthesis during established lactation. 
Studies in dairy cows have proven that short-term (9d) administration of bPL and 
bGH increase milk yield (Byatt et al., 1992b). A later study reported injections (7 days) 
of bPL or bPRL into dairy heifers stimulated mammary differentiation, such as increasing 
the serum concentration of a-lactabumin (Byatt et al., 1994). Bovine PL also stimulated 
milk yield of non-pregnant lactating cows and heifers after 7 to 9 days of treatment 
(Collier et al., 1995). In all cases, bPL appears to be less active than bGH and bPRL. 
These data strongly suggest that bPL is lactogenic, however the role of bPL in 
stimulating milk production may not be critical for the cow. 
The lactogenic activity of oPL has been investigated in mammary glands from 
rabbits and ewes (Servely et al., 1983). These data reported that oPL is more potent than 
oPRL in accumulating p-casein mRNA in mammary glands from rabbits but not from 
ewes. These findings provide hrther evidence that this placental hormone is not a potent 
lactogen in the homologous species. Since oPL binds with lower affinity to lactogenic 
receptors from ovine mammary gland explants, as compared to the rabbit mammary 
tissue (Sakal et al., 1997), this may explain why oPL is a less potent stimulator of P- 
casein and fatty acid synthesis, as compared to oPRL. 
There is conflicting evidence on the lactogenic activity of oPL in ewes. Min and 
his coworkers (1997) observed administration of bGH to the ewe for 5 days increased 
milk yield and milk composition. Serum concentrations of IGF-I and non-esterified fatty 
acid (NEFA) were elevated, but such effects were not observed in oPL-treated ewes, 
suggesting oPL is not lactogenic in sheep. Subsequent studies reported that treatment of 
bGH or oPL to lactating ewes for 5 days did not affect GH-R, IGF-I or IGFBP-3 mRNA 
in the mammary tissue or the number of GH-R in the liver. In addition, milk yield and 
hepatic expression of IGF-I mRNA increased following bGH but not oPL treatment 
(Bassett et al., 1998). These observations suggested that the effect of bGH on milk yield 
is partially mediated by an endocrine action of IGF-I, and oPL is not lactogenic in 
lactating ewes. It is speculated that the absence of plasma IGF-I concentrations during a 
short-term (5d) treatment period in ewes may be responsible for the lack of oPL effect on 
milk production. The findings that IGF-I significantly increased milk secretion, when 
infused directly to the mammary artery of goats (Prosser et al., 1990), together with the 
study reporting that bPL increased both milk yield and IGF-I in dairy cows treated with 
bPL for 9 days (Byatt et al., 1992b), may support this speculation. 
A thorough examination of the lactogenic role of oPL in pregnant ewes was 
performed due to the previous conflicting evidence (Kann et a]., 1999). Their results 
indicated that ewes treated with oPL for 10 days increased circulating IGF-I, and p-casein 
mRNA accumulation in ovine mammary explants. In goats, recombinant cPL also 
induced p-casein synthesis in rabbit and ovine mammary glands. However, cPL action 
was more potent than oPRL in mammary gland cultured from rabbits, but not from ewes 
(Sakal et al., 1998). Later work reported administration of oGH or oPL into mid-lactation 
ewes for 14 days increases milk production by up to 50% and 25%, respectively. Serum 
IGF-I concentrations were elevated by bGH, but not by oPL treatment (Leibovich et a]., 
2001a). These findings agreed with most studies, reporting that oPL treatments do not 
affect the circulating IGF-I concentrations in sheep (Ogawa et a]., 1995; Min et al., 1997; 
Bassett et al., 1998). These data suggested that both oGH and oPL display lactogenic 
effects in lactating ewes, but these hormones do not have the same mechanism of 
stimulating milk production, because only oGH treatment resulted in an increase in serum 
IGF-I concentrations. 
As stated previously, oPL displayed low activity in cells transfected with oPRL- 
Rs and no activity in cells transfected with oGH-Rs, but significantly greater activity in 
cells transfected simultaneously with both types of receptors (Herman et al., 2000). 
Together with the results that have been mentioned above, it could be interpreted that 
lactogenic effects of oPL (also likely for other ruminant PLs) are achieved either through 
homologous PRL-Rs, or through heterodimerization of homologous GH and PRL 
receptors (Leibovich et al., 2001 b), and that IGF-I could be one of the mediators involved 
in this process (Kann et al., 1999). 
Somatotrophic action: It is known that all three ruminant PLs have a low identity with 
GH, but they are able to interact with the GH (somatogenic) receptor from various 
species, thus displaying somatogenic activities both in vifro and in vivo. Studies across 
species have discovered that bPL binds to the GH-R in the liver membranes from rabbits 
(Eakle et al., 1982), cattle (Wallace and Collier, 1984; Staten et al., 1993), sheep (Emane 
et al., 1986), and ovine fetuses (Freemark and Handwerger, 1986). The binding affinity of 
oPL to the oGH-R in fetal and adult sheep liver was observed to be similar or greater than 
for oGH (Breier et al., 1994). Both cPL and oPL formed 1 :2 complexes with hGH-R, and 
rabbit GH-R (Sakal et al., 1998). These data provide evidence that ruminant PL have the 
ability to bind to GH-R from a number of species, and thus mimic some somatogenic 
effects similar to GH. 
Some investigators have proposed that ruminant PLs have potent somatogenic 
actions in heterologous species, but only display partial activities in homologous systems. 
In somatogenic bioassays, using either 3T3-L1 or 3T3-F442A rat-derived preadipocyte 
cells, the antimitogenic effect (Vashdi et a]., 1992) or inhibition of glucose uptake (Byatt 
et al., 1991) by bPL was slightly less potent or similar to that of hGH. In a rat hepatocyte 
culture, bPL was 100-fold more potent than bGH in inducing IGF-I mRNA expression 
(Warren et al., 1993). In mature female rats, rbPL was more active than bGH in 
stimulating weight gain and feed intake (Byatt et al., 1991). These effects were obtained 
without a concomitant increase in plasma IGF-I levels, as occurred with bGH. Based on 
the observations that bPL had a capacity of binding to both GH (Staten et al., 1993) and 
PRL (Scott et al., 1992) receptors, together with the report indicating that PRL 
significantly stimulated feed intake in rats (Gerado-Getterns et a]., 1989), it appears that 
bPL stimulates weight gain through a somatogenic mechanism or through another route, 
probably by lactogenic receptors. In sheep, the somatogenic activity of oPL was 
described in GH-deficient dwarf rats, where oPL and oGH are equipotent in stimulating 
serum IGF-I concentrations (Singh et al., 1992). Together, these findings suggest that 
ruminant PLs may bind and function through the GH-R in heterologous (rat) species. 
Contrasting results have been obtained regarding the different somatogenic effects 
of ruminant PLs between heterologous and homologous species. Studies in dairy cows 
have found that bPL does not mimic all somatogenic effects of bGH (Byatt et al., 1992b; 
Byatt et al., 1992~). Their results showed that administration of bGH to pregnant and 
non-pregnant dairy cows increased NEFA, glucose and insulin, whereas bPL failed to 
display any effects on these parameters. Both bGH and bPL increased IGF-I, but bPL was 
much less potent than bGH. In addition, both hormones decreased blood urea nitrogen, 
indicating increased nitrogen retention. The evidence indicated that, bPL only displays 
several somatotrophic effects as compared to bGH (Byatt et al., 1992a, 1992b), and bPL 
binds to GH-R in the bovine liver about 1.8 to 3.2 fold less potently than bGH (Byatt et 
al., 1991). This may explain why bPL acts as a partial somatotropin agonist in 
homologous systems. 
Another experiment with 2-month-old lambs has shown that, administration (5 
days) of bGH or bGH + oPL, but not of oPL alone, significantly increased circulating 
IGF-I concentrations, suggesting that oPL alone lacks somatogenic actions in postnatal 
lambs (Ogawa et al., 1995). In contrast, administration of roPL for 21 days increased 
growth and energy intake in 3-day-old lambs (Min et al., 1996). Other reports indicated 
the growth-promoting effects of roPL were similar to oGH when injected to 2-month-old 
lambs for 35 days (Leibovich et al., 2001a). The differences in these reports may be 
explained by differences in treatment periods, the age of lambs and experimental designs. 
As discussed before, homodimerization of the GH-R must occur, in order for the 
ligand-receptor complex to signal a biological response (Warren et al., 1999). This 
indicates that PL can simultaneously bind to both ruminant GH-R and PRL-R (Herman et 
al., 2000; Leibovich et al., 2001b). The co-administration of bGH and oPL to postnatal 
lambs significantly increased serum IGF-I concentrations, whereas bGH or oPL treatment 
alone had no such effects (Ogawa et al., 1995). Additionally, oPL enhanced the plasma 
levels of IGF-I in ewes even after 2 days of treatments (Kann et a]., 1999). It is 
emphasized again that in heterologous species, ruminant PLs display somatogenic 
activities, which are most likely mediated through GH-R. In homologous systems, 
however, ruminant PLs act by heterodimerizing of GH and PRL receptors. IGF-I has 
been suggested as one of the mediators regulating of these effects. 
Fetal growth - maternal and fetal metabolism: Placental lactogen has been shown to 
be present in high concentration in the fetus during the second half of gestation (Hill et al., 
1988; Byatt et al., 1987; Kappes et a]., 1992), suggesting PL may play a role in the 
regulation of fetal growth. Most of the information, regarding fetal and maternal 
metabolism is from experiments performed in sheep and humans. It is proposed that the 
effects of PL on fetal metabolism are mediated directly via fetal tissues, and indirectly via 
changes in maternal metabolism (Handwerger, 1991). Results from in vilro studies have 
indicated that oPL enhances the activity of ornithine decarboxylase (ODC) in the liver of 
rat fetuses, whereas this variable is not affected by oGH, oPRL, rat GH and rat PRL 
(Hurley et al., 1980). These results suggested an important role for oPL in the regulation 
of fetal growth via ODC, a vital enzyme for controlling cellular growth. In addition, oPL 
stimulated IGF-I1 synthesis in fetal rat fibroblasts (Adams et al., 1983), amino acid (AA) 
transport in fetal rat diaphragm (Freemark et al., 1982 & 1983) and glycogen storage in 
the fetal rat liver (Freemark and Handwerger 1984 & 1985), while oGH displayed little or 
no effects on these parameters. In the ovine fetal liver, oPL promoted glucose 
incorporation into glycogen with a greater potency than was seen with oGH and oPRL 
(Freemark and Handwerger, 1986). The anabolic effects of human PL on fetal 
metabolism have been implicated, for example, promoting AA uptake, DNA synthesis 
and IGF-I production in human fetal myoblasts, fibroblasts and hepatocytes in culture 
(Hill et al., 1986; Strain et al., 1987). The influence of rat PL on embryonic growth and 
development was recently noted (Seoyum et al., 1999). The observations that GH has no 
significant effect on fetal growth and metabolism, when infused in late-gestational fetal 
sheep for 10 days (Bauer et al., 2000), together with the lack of GH-R in fetal tissues 
until term (Freemark and Handwerger, 1986), suggest that PL may hnction as a "fetal 
growth hormone". 
Concentrations of hPL in the fetus have shown to correlate positively with fetal 
IGF-I, IGF-I1 and IGFBP levels, suggesting the role of PL in fetal IGF synthesis 
(Lassarre et al., 1991). Another report was consistent with previous findings, implying 
infusion of oPL into the ovine fetus for 14 days, at a late stage of gestation (day 122), 
elevated serum IGF-I concentrations and hepatic glycogen deposition (Schoknecht et al., 
1996). A study with pregnant ewes has demonstrated that, roPL treatment does not 
increase IGF-I in either the mother or fetus, but significantly increases the IGFBP-3 gene 
expression in the fetal liver, suggesting oPL may have an indirect effect on fetal growth 
by changing IGFBP-3 production (Currie et al., 1996). Both IGF-I and IGF-I1 have been 
demonstrated as important fetal growth factors (Owen et al., 1991), thus PL in the fetus 
may be a regulator of fetal growth by controlling IGF-I and IGF-I1 secretion. 
Several researches have pointed out that, PL may regulate the partitioning of 
maternal nutrients to support fetal growth, perhaps via IGFs, in humans (Handwerger et 
al., 1991) and sheep (Anthony et al., 1995a). Contradictory results have been reported on 
maternal and fetal metabolism in sheep. Intravenous infusion (8h) of partially purified 
oPL into fasting pregnant and non-pregnant ewes reduced NEFA, glucose and amino 
nitrogen levels, but elevated plasma insulin concentrations (Handwerger et al., 1976). 
Conversely, infusion (36h) of an ovine placental extract, enriched in oPL, to non- 
pregnant ewes induced opposite effects, with no effects on insulin (Thordarson et al., 
1987). Another study reported that antibody neutralization of maternal oPL (12h) 
significantly increased plasma insulin levels, reduced free fatty acid (FFA) concentrations, 
and had no effect on body glucose metabolism (Waters et al., 1985). The conflicting 
results could be interpreted as differences in nutritional status of the ewes, treatment 
periods and experimental models. Nevertheless, these results show that oPL may modify 
maternal metabolism to provide nutrients for fetal growth. 
Additional data have demonstrated the role of PL in the metabolic adaptation 
during pregnancy. Prolonged fasting (72h) of pregnant ewes increased oPL 
concentrations in both maternal and fetal serum (Brinsmead et al., 1981), and reduced the 
number of PL receptors in the maternal and fetal liver (Freemark et al., 1989 and 1992). 
However, by infusing glucose into fasted ewes, only the numbers of receptors in the fetal 
liver were reversed (Freemark et al., 1992). This may indicate the metabolic adaptation of 
the mother during nutritional stress, thus providing sufficient nutrients that are used to 
support the developing fetus. Torto (1 994) found Holstein cows fed with low protein, all- 
forage diets also increased maternal bPL concentrations. Pregnant women, who fasted for 
84-90 hours during mid-pregnancy, increased their plasma hPL concentrations, 
coincident with a rise in FFAs (Kim et al., 1971; Tyson et al., 1971), decreased glucose 
and insulin, but elevated ketone acid levels in their blood (Felig and Lynch, 1970). It is 
believed that nutritional deprivation during fasting may be responsible for the elevation 
of the plasma PL concentration, and that an increase in hPL concentration during 
starvation may facilitate the mobilization and utilization of maternal FFAs for energy, 
thereby sparing maternal glucose for the fetus. 
It has been suggested that, the main effects of oPL and hPL on maternal and fetal 
metabolism are increased gluconeogenesis and lipid mobilization, whereas bPL has no 
such obvious effects (Byatt et a1 1992c; Handwerger and Freemark 2000). Earlier works 
with pregnant and non-pregnant cattle had shown that rbPL does not affect plasma 
concentrations of glucose, NEFAs or insulin, but increases plasma IGF-I and IGF-I1 to a 
lesser extent, as compared to bGH (Byatt et a]., 1992~). Apparently, bPL displays 
different metabolic and hormonal changes in both pregnant and non-pregnant cows, as 
compared to bGH. This emphasizes bPL regulateion of the maternal intermediary 
metabolism, perhaps through a specific receptor (Byatt et al., 1992~).  Additionally, short- 
term (9d) treatment with rbPL induced an acute elevated feed intake in non-pregnant 
Holstein dairy cows (Byatt et al., 1992b). This effect was also obtained in sheep and 
cattle treated with bGH, but only afier several weeks of continuous treatments (Bauman 
et al., 1985; Sandles et al., 1988). These data raise a possibility that bPL may regulate 
fetal growth via enhancing dry matter intake. 
In summary, PL influences fetal growth by acting both on the fetus and the 
mother. These effects are exerted by altering maternal metabolism to ensure an adequate 
flow of substrates to the growing fetus, and by stimulating the fetus to use these 
substrates. This placental hormone may act through one or more IGF productions, and 
also through a structurally distinct PL-R, although the later theory remains controversial. 
Chapter 2 
IMMUNOPURWICATION OF BOVINE PLACENTAL LACTOGEN 
Introduction 
Placental lactogens (PL) have been isolated and purified in a number of various 
species, including human (Friesen, 1965), monkey (Shome & Friesen 1971), mouse 
(Colosi et al., 1982), rat (Robertson & Friesen 1979,  sheep (Marta1 & Djiane 1975; Chan 
et al., 1976; Hurley et al., 1977; Reddy and Watkins 1978, Warren et al., 1990a) and goat 
(Currie 1990). The purification scheme for bovine placental lactogen (bPL) is more 
difficult than other placental proteins. Bovine PL was first isolated and purified from 
placental tissue by Bolander & Fellows (1976). This report demonstrated that the 
hormone was purified to approximately 99% homogeneity with an estimated molecular 
weight (MW) of 22,150 and its isoelectric point (PI) at 5.9. Isoelectric point is known as a 
pH at which a protein molecule bears no charge. This value varies between proteins. 
Additional purification studies were conducted in attempt to repeat the previous methods, 
but the bPL preparation yielded different characteristics. Murthy et a1 (1982) detected 
one form of bPL at 30,000 - 32,000 MW and 5.5 pl. Subsequent studies showed a 4,200- 
fold purification of bPL with several forms of bPL at 3 1,000 MW and several pI ranges 
from 5.39 to 5.85 (Arima and Bremel, 1983). Their purification procedures involved 
extraction and ammonium sulfate precipitation, followed by ultrafiltration, gel filtration, 
anion exchange, hydroxylapatite, chromatofocusing and final gel filtration 
chromatography. Wallace (1986) developed an efficient system for the purification of 
bPL from bovine fetal cotyledons using the initial purity of material from culture medium 
thus eliminating the need for an ammonium sulfate precipitation step. Results showed 
that bPL was purified 616 fold and that two forms existed at 30,000 MW and two pI of 
4.95 and 5.15. The existence of multiple forms of bPL with various pIs was identified 
from most previous works, using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) or chromatofocusing column. 
In order to examine the structure and biological functions of PLs, there is a need 
for large quantities of purified molecules for additional in vitro and in vivo studies. 
Several laboratories have prepared recombinant bPL (Krivi et al., 1989), oPL (Colosi et 
al., 1989; Sakal et al., 1997), and cPL (Sakal et al., 1998) in sufficient amounts. Most of 
the recent studies, related to bPL, have utilized a recombinant molecule, which is 
structurally different from the native bPL (Byatt et al., 1992). The native molecule 
contains both 0- and N-linked oligosaccharide in its structure and this makes it a higher 
MW molecule of 3 1,000 - 33,000 (Shimomura and Bremel 1988). There is no indication 
that PLs of sheep, goat and human are glycosylated. This explains why the MW of these 
PLs are lower (approximately 22,000) compared to that of bPL (Chan et al., 1976; Currie 
et al., 1990; Friesen, 1965). The enzymatic removal of N-linked sugar from native bPL 
increased the binding affinity of somatotropin receptor for bPL by about 1.2-2.3 fold. 
However, removal of 0-linked oligosaccharide had a small effect on either somatogenic 
or lactogenic bindings (Byatt et al., 1990). 
The purification of endogenous bPL, in quantities sufficient for complete 
physiological studies in vivo has not yet been reported. The low yield of native PL from 
bovine placenta may be one of the reasons for this limitation. An attempt has been made 
to clone the bPL cDNA into a mammalian expression vector, followed by an 
amplification of the rbPL jnto E. coli cells and finally transfection of the recombinant 
molecule into mouse fibroblast cells (Doucette, 2003). It was expected that the mouse 
cells would be able to produce the bPL complete with the post-translational 
characteristics, which are observed in the native protein. The bPL cDNA was 
successfi~lly cloned into the pcDNA 3.1 (+) vector, but the transfection process was not 
employed efficiently. The primary reason was that the cloned bPL gene was missing the 
third exon, which is known to be responsible for protein production. 
Immunologic methods, such as affinity chromatography have proven to be a 
specific technique for the purification of  biomolecules. One-step purification of nisin A, 
an antimicrobial peptide used in the food industry, by immunoafinity chromatography 
has been reported (Suarez et al., 1997). The purification procedure resulted in 72% final 
yield and a 10-fold increase in specific activity. A similar method was accomplished to 
purify bPL from bovine fetal cotyledons, using the Affinica Antibody Orientation column, 
containing protein A agarose (Torto, 1994). It was hoped that this process would be more 
efficient than previously described methods in terms of rapidity, higher final yield and 
purity. The purification process was carried out starting from bovine fetal cotyledon 
homogenate, followed by an anion exchange chromatography and finally an Affinica 
column. The results showed that the Afinica column was not efficient to fully purify bPL, 
as a very poor final yield was achieved (3.6%). 
Currently, immunomagnetic separation has been shown to be a very effective 
method for isolating various proteins, nucleic acids and cell types from a complex 
mixture. The principle of this technique involves coupling of an affinity ligand onto the 
magnetic particles. Beads are then directly added to the sample containing target 
molecules. By doing this, the target has a chance to interact with an affinity group on the 
bead. Magnetic separation is achieved by placing the magnet outside a reaction flask. 
Thus the use of a centrifuge for concentration of molecules is not necessary. After 
washing the beads, the target molecule is eluted at low pH or in a high salt concentration. 
The application of a magnetic bead to separate a monoclonal antibody (Quitadamo and 
Schelling, 1998) and a human transferin receptor (Karlsson and Platt, 1991) has proven to 
be more efficient than traditional affinity chromatography. One experiment was 
conducted to purify bPL from ammonium sulfate precipitate preparation, utilizing this 
novel approach (Miller, 1996). The purity of bPL at the end of purification was very low 
(10%). A hrther purification step was accomplished, using anion exchange 
chromatography (DE 52 diethylaminoethyl cellulose), but this chromatographic step did 
not provide adequate amounts and purity of bPL. Recombinant molecules, instead of the 
native protein, were used for fkrther study in this experiment. 
Since the previous procedures did not produce an efficient amount of purified 
protein from the bovine placental cotyledons, our challenge was therefore to establish a 
more rapid and specific method for the purification of bPL, using the immunomagnetic 
separation method. If a high yield and purity of the native molecule could be obtained, a 
comparative study of differences in biological activity between the native and 
recombinant proteins would be possible. 
Materials and methods 
Purification of antibody against bovine placental lactogen: Bovine placental lactogen 
was partially purified using the immunopurification method. The first step of bPL 
purification was to isolate an antibody (Ab) against bPL. This Ab was produced in sheep, 
called sheep anti-rabbit Ab and was donated by Monsanto Corporation (Monsanto, St. 
Louis, MO). The Ab to bPL was purified using a 2 ml column of Immobilized Protein G 
(Pierce Biotechnology). The kit contained binding buffer (pH 5) ,  elution buffer (pH 2.8) 
and immobilized protein G, which was isolated from group G streptococci. This type of 
protein binds to the mammalian IgG through their Fc regions and allows non-IgG 
components of the sample to pass on through the column. To facilitate binding, 2ml of  
serum sample was mixed with 2 ml of binding buffer. The sample was then loaded onto 
an equilibrated protein column and allowed to drain through the column. The column was 
washed by adding 10 ml binding buffer. The bound IgGs were recovered by adding 6 ml 
of elution buffer and immediately started to collect a 1.0 ml fraction into the first 
numbered collection tube. Column fractions were monitored for protein, using a 
spectrophotometer at 280 nm absorbance. The fractions having high absorbance, which 
contain the purified IgG, were combined. Concentration of IgG is described in mdml = 
(A280 / 14) x 10. 
Prior to introducing the purified Ab to the magnetic immobilization kit, the Ab 
activity was monitored by using a radioimmunoassay (RIA), then linked to an amine 
terminated biomag (Polysciences, Inc.). The coupling efficiency determined as the 
percent protein uptake was 79.8%, which met the requirement of manufacturer's 
recommendations (> 60%). 
Purification of endogenous bPL: The ammonium sulfate (A.S.) precipitation, 
containing bPL from bovine placental cotyledons, was donated by Dr. Ron Kensinger 
(Pennsylvania State University).One gram of dried A.S. was dissolved in 40 ml Tris HCl 
buffer (IOrnM pH 7.5) and stored in the refrigerator overnight. Next day, the homogenate 
was centrifuged at 10,000 x g for 30 min. The supernatant was collected and mixed with 
5 ml biomag. This mixture was then loaded into a flask and rotated with low speed, at 
room temperature for 30 min. The solution was applied to the magnet for 15 min to pull 
bPL out of the solution. The liquid was drained off and saved for later analysis. The 
biomag was washed two times with Tris buffer (1OmM pH 7.5) and the magnet was 
applied between washes. Removal of bPL from the biomag was done by adding 10 ml 
glycine (0.1 M pH 3.2). Finally, 3.33 ml40% sucrose was added to the glycine mixture to 
prevent protein aggregation and then stored in a refrigerator for analysis. 
At each step of the purification process, the protein content of the sample was 
estimated, measuring the absorbance of light at 280 nanometers with a spectrophotometer. 
The Bradford assay provided by Sigma was further used to re-examine the concentration 
of protein in the sample. This assay works by the action of the Brilliant Blue dye which 
specifically binding to the protein contained in the sample. This binding causes a shift in 
the absorption maximum of the dye from 465 to 595. The resultant increase in 
absorbance at 595 is recorded and the protein concentration is determined by comparison 
to a standard curve. A micro 2 ml assay protocol was utilized in our experiment following 
the instructions of the manufacturer. 
The presence of bPL in the sample was detected by a double Ab RIA procedure, 
according to the method described by Wallace (1986). Each sample was run in duplicate 
and a standard curve with rbPL concentration ranging from .05 to 5 ng per tube was also 
constructed in duplicate. Recombinant bPL used for standards and for radioiodination 
was provided from Monsanto Corporation. The assay was run as follows: 100 pl of 
sample or standard was combined with 2 0 0 ~ 1  assay buffer (25 mM Tris-HCI, 50mM 
EDTA, 0.1% BSA, pH 7.8), plus 200 p1 of the first Ab (rabbit anti-bPL IgG, diluted 
1:15,000 in 1:400 normal rabbit serum in Tris buffer). The contents were mixed and 
incubated at 4°C for 24 h. The next day, each test tube was combined with 1 0 0 ~ 1  of 
iodinated hormone ( I ' ~ ~  bPL 20,000 cpm) and incubated at 4OC overnight. On the third 
day, antibody bound hormones were precipitated by addition of 2 0 0 ~ 1  of the second Ab 
(sheep anti-rabbit IgG) and 5 0 0 ~ 1  of 6% polyethylene glycol (PEG). Tubes were 
vortexed and incubated for 30 min at 4OC. Tubes were centrifbged at 1000 x g for 30 min 
and the supernatant was carefully decanted. Tubes were dried and the radioactivity of the 
precipitates was then counted in a Gamma Tract gamma counter. From the standard curve 
the unknown bPL in the sample could be determined. 
Fractions that contained active materials were pooled and concentrated by lyophilization. 
The purity of the bPL was fbrther confirmed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE). 
Results and discussion 
Bovine PL was purified from ammonium sulfate precipitate sample, using a novel 
immunomagnetic purification technique. In our experiment, 25 samplings were run 
following the procedures described above. The results of purifications are shown in Table 
1 and Table 2 as follows. 
Table 1 : Immunomagnetic purification of bovine placental lactogen (bPL) 
1 Total 1 298.05 1 2241.4 1 0.13 
Table 2: A summary of the purification procedure of bPL fiom ammonium sulfate precipitation 
(**): The Bradford method 
Initially, the purity of bPL was determined to be 13%, based on the value of the 
absorbance of light at 280 nanometers with a spectrophotometer to determine the protein 
content in the sample. We suspect that the purity of the sample preparation may be 
underestimated, as some colored components contained in the bPL preparation may 
interfere with the reading of the spectrophotometer, giving us a false estimate of protein. 
Further investigation was, therefore, carried out using the Bradford assay to re-examine 
the protein level in the sample. The purity level of bPL was re-estimated to be 
approximately 25%, which was higher than results obtained in the previous studies. In 
these experiments, the bPL molecule was purified starting from an ammonium sulfate 
precipitate sample, which is similar to that utilized in our experiment. The purity level of 
bPL was reported to be 9% and 10% by Torto (1994) and Miller (1996), respectively. 





purification approaches and some current studies using the magnetic beads to isolate 







pg bPL/pg protein 
0.007 
(*): The 280 nrn absorbance method 
298.05 1200.00** 0.25 
Complicated devices required for the purification protocols are not necessary and only 
one-step purification is involved. At present, we have not investigated the exact cause of 
these limitations. We are considering that the use of a low pH eluting buffer (glycine HC1, 
pH 3.2) may have partially influenced the integrity of  the immunoaffinity complex, 
which also may explain the low yield and purity observed in our study. There is evidence 
to suggest that the optimal elution buffer used in the magnetic bead separation has 
increased the yield and purity of the targeted molecules, minimizing the dissociation of 
protein. Recent investigations demonstrated the physical degradation of magnetic beads 
when using the low pH eluting buffer in their experiments, including urea 6 M-formic 
acid O.lM, pH 3.5 and glycine HCL pH 2.5 (Prioult et al., 2000). The efficiency of using 
a magnetic bead purification method for isolating mouse (Quitadamo & Schelling, 1998) 
and rabbit (Quitamo et al., 2000) monoclonal antibodies has been reported. The use of 
extreme pH in these studies has been avoided to maximize the recovery of 
immunoreactive proteins. The earlier data achieved 70% for magnetic bead purification 
efficiency, using high salt instead of low pH for antibody elution. The latter report 
indicated the rabbit IgG was eluted from magnetic beads with acetic acid 0.5M, pH 4.5 to 
avoid harsh condition. The average percent of IgG yield estimated was 78%. 
Furthermore, different sizes of magnetic beads, used in the purification process 
also have been reported to influence the recovery and specificity of the target molecules. 
The advantage of using micromagnetic beads (diameter < 50nm) over the large beads (> 
500 nm) in detecting bacterial cells has been demonstrated (Jacobsen et al., 1997; 
Miltenyi et a]., 1990). Results showed the recovery of bacterial cells up to 95% by using 
the micromagnetic bead without the aggregation of beads (Jacobsen et a]., 1997). 
In summary, immunomagnetic separation was used to purify bPL from an 
ammonium sulfate precipitation sample, yielding a purity level of 25%. The SDS-PAGE 
analysis showed the presence of a band about 32,000 MW, however, some contaminants 
appeared on the gel thus hrther isolation steps are needed. It is not clear what is the 
primary cause influencing the results, although some factors such as elution buffer and 
the size of the magnetic beads have been noted to affect the purity and final yield of 
various proteins or cells. In general, it is difficult to compare purification processes that 
involve different target proteins. Purification schemes for bPL may require some optimal 
conditions as indicated above, but to elucidate this needs hrther investigation. 
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